100 mg Delamanid
242-12-232
Phase 1 small_molecule completed
Quick answer
100 mg Delamanid for Multidrug Resistant Tuberculosis is a Phase 1 program (small_molecule) at Otsuka Beijing Research Institute with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Otsuka Beijing Research Institute
- Indication
- Multidrug Resistant Tuberculosis
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed